WO2005013907A3 - Pyrrolo[1,2-b]pyridazine derivatives - Google Patents

Pyrrolo[1,2-b]pyridazine derivatives Download PDF

Info

Publication number
WO2005013907A3
WO2005013907A3 PCT/US2004/025590 US2004025590W WO2005013907A3 WO 2005013907 A3 WO2005013907 A3 WO 2005013907A3 US 2004025590 W US2004025590 W US 2004025590W WO 2005013907 A3 WO2005013907 A3 WO 2005013907A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolo
pyridazine derivatives
compounds
metabolic
modulate
Prior art date
Application number
PCT/US2004/025590
Other languages
French (fr)
Other versions
WO2005013907A2 (en
Inventor
Brian M Fox
Kiyosei Iio
Takashi Inaba
Frank Kayser
Kexue Li
Shoichi Sagawa
Masahiro Tanaka
Atsuhito Yoshida
Original Assignee
Tularik Inc
Japan Tobacco Inc
Brian M Fox
Kiyosei Iio
Takashi Inaba
Frank Kayser
Kexue Li
Shoichi Sagawa
Masahiro Tanaka
Atsuhito Yoshida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc, Japan Tobacco Inc, Brian M Fox, Kiyosei Iio, Takashi Inaba, Frank Kayser, Kexue Li, Shoichi Sagawa, Masahiro Tanaka, Atsuhito Yoshida filed Critical Tularik Inc
Priority to JP2006522779A priority Critical patent/JP2007501801A/en
Priority to EP04780428A priority patent/EP1653969A4/en
Publication of WO2005013907A2 publication Critical patent/WO2005013907A2/en
Publication of WO2005013907A3 publication Critical patent/WO2005013907A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
PCT/US2004/025590 2003-08-07 2004-08-06 Pyrrolo[1,2-b]pyridazine derivatives WO2005013907A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006522779A JP2007501801A (en) 2003-08-07 2004-08-06 Pyrrolo [1,2-b] pyridazine derivatives
EP04780428A EP1653969A4 (en) 2003-08-07 2004-08-06 Pyrrolo 1,2-b pyridazine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49399703P 2003-08-07 2003-08-07
US60/493,997 2003-08-07

Publications (2)

Publication Number Publication Date
WO2005013907A2 WO2005013907A2 (en) 2005-02-17
WO2005013907A3 true WO2005013907A3 (en) 2005-04-21

Family

ID=34135309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/025590 WO2005013907A2 (en) 2003-08-07 2004-08-06 Pyrrolo[1,2-b]pyridazine derivatives

Country Status (4)

Country Link
US (1) US7300932B2 (en)
EP (1) EP1653969A4 (en)
JP (1) JP2007501801A (en)
WO (1) WO2005013907A2 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
NZ587106A (en) 2004-12-14 2012-03-30 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Fast Dissociting Dopamine 2 Receptor Antagonists
CN101346387A (en) 2005-12-22 2009-01-14 阿斯利康(瑞典)有限公司 Pyrimido- [4, 5-]-oxazines for use as DGAT inhibitors
SG10201408806UA (en) 2006-03-31 2015-02-27 Novartis Ag New compounds
JP2009538891A (en) 2006-05-30 2009-11-12 アストラゼネカ アクチボラグ 1,3,4-oxadiazole derivatives as DGAT1 inhibitors
CN101472905B (en) 2006-05-30 2011-12-14 阿斯利康(瑞典)有限公司 Substituted 5- phenylamino- 1, 3, 4-oxadiaz0l-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
AU2007255180B2 (en) 2006-06-08 2011-02-03 Astrazeneca Ab Benzimidazoles and their use for the treatment of diabetes
EP2044055A4 (en) * 2006-07-21 2011-03-23 Takeda Pharmaceutical Amide compounds
BRPI0715160A2 (en) 2006-08-08 2013-06-11 Sanofi Aventis arylamimoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, drugs comprising these compounds, and their use
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Fast Dissociating Dopamine 2 Receptor Antagonists
WO2008073865A2 (en) * 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Fast -Dissociating Dopamine 2 Receptor Antagonists
MX2009011416A (en) 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists.
RU2464268C2 (en) 2007-04-23 2012-10-20 Янссен Фармацевтика Н.В. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
CA2695434A1 (en) * 2007-08-17 2009-02-26 Astrazeneca Ab Chemical compounds 979
ES2499018T3 (en) 2007-09-20 2014-09-26 Irm Llc Compounds and compositions as modulators of the activity of GPR119
AR066169A1 (en) * 2007-09-28 2009-07-29 Novartis Ag DERIVATIVES OF BENZO-IMIDAZOLES, USEFUL FOR DISORDERS ASSOCIATED WITH THE ACTIVITY OF DGAT
KR20100099738A (en) 2007-12-20 2010-09-13 아스트라제네카 아베 Carbamoyl compounds as dgat1 inhibitors 190
WO2009126624A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
US8394823B2 (en) * 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
CN102159554B (en) 2008-07-03 2014-09-24 詹森药业有限公司 Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
UY31968A (en) 2008-07-09 2010-01-29 Sanofi Aventis NEW HETEROCYCLIC DERIVATIVES, THEIR PROCESSES FOR THEIR PREPARATION, AND THEIR THERAPEUTIC USES
EP2307374B1 (en) 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
CA2743609A1 (en) 2008-11-19 2010-05-27 Schering Corporation Inhibitors of diacylglycerol acyltransferase
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CN102395572A (en) * 2008-12-19 2012-03-28 阿斯利康(瑞典)有限公司 1,3,4-oxadiazole derivatives and their uses to treat diabetes
US11033523B2 (en) 2009-04-29 2021-06-15 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
RU2011152517A (en) 2009-06-19 2013-07-27 Астразенека Аб Pyrazinecarboxamides as DGAT1 Inhibitors
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
CN102482312A (en) 2009-08-26 2012-05-30 赛诺菲 Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
AU2010303780B2 (en) 2009-10-09 2014-02-20 Irm Llc Compounds and compositions as modulators of GPR119 activity
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
CN102834099B (en) 2010-03-30 2015-05-27 诺华有限公司 Uses of DGAT1 inhibitors
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
WO2014081995A1 (en) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
US9974759B2 (en) 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
CA2926596C (en) * 2013-10-16 2020-07-14 Shanghai Yingli Pharmaceutical Co., Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
EP3592739A1 (en) * 2017-03-07 2020-01-15 H. Hoffnabb-La Roche Ag Oxadiazole transient receptor potential channel inhibitors
CN109232575B (en) * 2017-07-10 2022-01-25 中国科学院上海药物研究所 Pyrrole [1,2-b ] pyridazine compound or pharmaceutically acceptable salt thereof and application thereof
SG11202003005PA (en) * 2017-10-04 2020-04-29 Japan Tobacco Inc Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof
EP3710005B8 (en) 2017-11-17 2023-06-14 Academia Sinica SUBSTITUTED PYRROLO[2,1,-ALPHA]PHTHALAZINES AND BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINES AND THEIR USES IN THE TREATMENT OF CANCER
PE20220281A1 (en) 2019-03-19 2022-02-25 Boehringer Ingelheim Animal Health Usa Inc AZA-BENZOTHIOPHENE AND AZA-BENZOFURAN COMPOUNDS AS ANTIHELMINTICS
CN112142744A (en) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and uses thereof
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472389B1 (en) * 1998-05-21 2002-10-29 Shionogi & Co., Ltd. Pyrrolo[1,2-b] pyridazine derivatives having sPLA2 inhibitory effect

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPH05213985A (en) 1992-02-10 1993-08-24 Mitsubishi Kasei Corp Pyrrolecarboxylic acid coenzyme a derivative
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
SV2002000205A (en) 1999-11-01 2002-06-07 Lilly Co Eli PHARMACEUTICAL COMPOUNDS REF. X-01095
JP2002284741A (en) 2001-03-23 2002-10-03 Kitasato Inst:The Roselipin derivative
IL160253A0 (en) 2001-08-09 2004-07-25 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
KR100460438B1 (en) 2001-12-01 2004-12-08 한국생명공학연구원 Polyacetylene group compounds, novel inhibitors of acyl CoA:diacylglycerol acyltransferase and the process for preparing thereof
JP4164645B2 (en) 2002-08-09 2008-10-15 株式会社大塚製薬工場 DGAT inhibitor
MXPA05005425A (en) 2002-11-22 2005-11-23 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocycles.
KR20060114376A (en) 2004-01-30 2006-11-06 니뽄 다바코 산교 가부시키가이샤 Anorectic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472389B1 (en) * 1998-05-21 2002-10-29 Shionogi & Co., Ltd. Pyrrolo[1,2-b] pyridazine derivatives having sPLA2 inhibitory effect

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1653969A4 *

Also Published As

Publication number Publication date
US20050070545A1 (en) 2005-03-31
EP1653969A2 (en) 2006-05-10
US7300932B2 (en) 2007-11-27
WO2005013907A2 (en) 2005-02-17
EP1653969A4 (en) 2006-12-20
JP2007501801A (en) 2007-02-01

Similar Documents

Publication Publication Date Title
WO2005013907A3 (en) Pyrrolo[1,2-b]pyridazine derivatives
WO2004047755A3 (en) Fused bicyclic nitrogen-containing heterocycles
WO2003024395A3 (en) Linked biaryl compounds
WO2007044426A3 (en) Pyrazolopyrimidines as protein kinase inhibitors
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2006012502A3 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
WO2004026310A8 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
WO2005077954A3 (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
HK1071756A1 (en) Pyrazolopyrimidines suitable for the treatment of cancer diseases
WO2006128022A3 (en) Solid compositions and methods for treating middle-of-the night insomnia
AU2003297684A1 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
WO2006107853A3 (en) Pyrazolopyridine-1,4-diamines and analogs thereof
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2007058942A3 (en) Imidazopyrazines as protein kinase inhibitors
WO2007058873A3 (en) Imidazopyrazines as cyclin depentend kinase inhibitors
WO2004026867A3 (en) Imidazopyridines as cyclin dependent kinase inhibitors
WO2005062881A3 (en) Gene therapy using transposon-based vectors
WO2000008202A3 (en) 3-methylidenyl-2-indolinone modulators of protein kinase
WO2006004703A3 (en) PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
WO2007111720A3 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004780428

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006522779

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004780428

Country of ref document: EP